Testing antiviral drugs to control Epstein-Barr virus in MS
Part of Brain & nervous system, Immune system & allergy clinical trials.
This Phase 2 study tests whether certain antiviral medicines can reduce Epstein-Barr virus (EBV) activity. If you have multiple sclerosis and evidence of EBV infection, the results may help clarify new ways to target EBV-related disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have a confirmed diagnosis of multiple sclerosis
- You agree to sign informed consent and be available for all study visits and procedures
- Your EBV blood tests are positive (EBV testing will be done at screening, and negative results mean you’re not enrolled)
- You are able to do required blood and urine testing used to check safety (including kidney function and phosphorus levels)
- If you are not pregnant and not breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether a patient’s own immune cells (made to target a common virus called EBV) are safe and practical for people who have their first episode that strongly suggests multiple sclerosis. If it works well, it could offer a new way to treat early disease—but the main goal now is safety and feasibility.
This study looks at whether people with multiple sclerosis (MS) in Egypt have higher levels of antibodies (proteins that fight infection) to the Epstein-Barr virus (EBV, a common virus that causes mono) compared to healthy people. The goal is to learn more about the possible link between EBV and MS, which might help with future understanding or treatment.
This trial tests an experimental oral drug called VT7208 in both healthy volunteers and people with multiple sclerosis (MS). The goal is to see if it is safe and how the body processes it, which could lead to a new treatment option for MS.
This trial tests a combination of drugs (PD-1 inhibitor, tenofovir, chidamide, and lenalidomide) to treat diseases caused by the Epstein-Barr virus (EBV). The goal is to see if this combination can reduce the virus and improve symptoms.
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
This study tests two experimental vaccines (V350A and V350B) designed to prevent Epstein-Barr virus infection. It is looking for healthy adolescents and adults to see if the vaccines are safe and produce a good immune response.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.